A hybrid quantum-classical fusion neural network to improve protein-ligand binding affinity predictions for drug discovery

L. Domingo,M. Chehimi,S. Banerjee,S. He Yuxun,S. Konakanchi,L. Ogunfowora,S. Roy,S. Selvaras,M. Djukic,C. Johnson
2024-09-03
Abstract:The field of drug discovery hinges on the accurate prediction of binding affinity between prospective drug molecules and target proteins, especially when such proteins directly influence disease progression. However, estimating binding affinity demands significant financial and computational resources. While state-of-the-art methodologies employ classical machine learning (ML) techniques, emerging hybrid quantum machine learning (QML) models have shown promise for enhanced performance, owing to their inherent parallelism and capacity to manage exponential increases in data dimensionality. Despite these advances, existing models encounter issues related to convergence stability and prediction accuracy. This paper introduces a novel hybrid quantum-classical deep learning model tailored for binding affinity prediction in drug discovery. Specifically, the proposed model synergistically integrates 3D and spatial graph convolutional neural networks within an optimized quantum architecture. Simulation results demonstrate a 6% improvement in prediction accuracy relative to existing classical models, as well as a significantly more stable convergence performance compared to previous classical approaches.
Quantum Physics,Machine Learning
What problem does this paper attempt to address?
The paper attempts to address the challenge of accurately predicting protein-ligand binding affinity in drug discovery. Specifically, existing methods face issues of poor convergence stability and insufficient prediction accuracy when predicting binding affinity. Additionally, while existing quantum machine learning (QML) models outperform traditional machine learning (ML) models under certain conditions, their performance in practical applications is hindered by noise in noisy intermediate-scale quantum (NISQ) devices, leading to unstable performance. To address these issues, the paper proposes a new hybrid quantum-classical deep learning model aimed at improving the prediction accuracy of binding affinity in drug discovery. By optimizing the quantum circuit architecture, the model combines 3D convolutional neural networks (3D-CNN) and spatial graph convolutional neural networks (SG-CNN) to achieve higher prediction accuracy and more stable convergence performance. Furthermore, to enable scalable deployment of this framework on NISQ devices, the paper also introduces a new quantum error mitigation algorithm that effectively mitigates the impact of noise without adding extra overhead during the training and testing phases.